NCT04212221 2024-07-23
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
Zai Lab (Hong Kong), Ltd.
Phase 1/2 Terminated
Clinical Trials
12 trialsNCT00355238 2023-12-01
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT01367275 2020-09-03
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00908752 2019-12-02
BRISK TA
Bristol-Myers Squibb
Phase 3 Completed
NCT00825955 2019-10-09
BRISK PS
Bristol-Myers Squibb
Phase 3 Completed
NCT00594984 2015-11-04
Phase I/II Combination With Irinotecan- Erbitux
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01108705 2015-10-12
BRISK-APS
Bristol-Myers Squibb
Phase 3 Terminated
NCT00633789 2015-10-09
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Bristol-Myers Squibb
Phase 2 Completed
NCT01540461 2014-07-08
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
Bristol-Myers Squibb
Phase 1 Completed
NCT00437424 2011-05-04
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
Bristol-Myers Squibb
Phase 1 Completed
NCT00207051 2011-01-25
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
Bristol-Myers Squibb
Phase 1 Completed
NCT00300027 2010-03-02
Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies
Bristol-Myers Squibb
Phase 1 Terminated